Skip to main content

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

Recruiting · Phase 2 · NCT06577441

Conditions: Myelodysplastic Syndrome

At a glance

Research payments reported, 2025
$3.2M
U.S. investigators named
37
Sites paid
91
Planned or actual enrollment
54

About the trial

Sponsor
National Cancer Institute (NCI)
Tested
Biospecimen Collection (procedure), Bone Marrow Aspiration (procedure), Bone Marrow Biopsy (procedure), Decitabine and Cedazuridine (drug), Enasidenib (drug)
Dates
Started 2025-06-12; completion 2027-03-01
Results posted
Not yet

This phase II MyeloMATCH treatment trial compares the usual treatment of cedazuridine-decitabine (ASTX727) to the combination treatment of ASTX727 and enasidenib in treating patients with higher-risk, IDH2-mutated myelodysplastic syndrome (MDS). ASTX727 is a combination of two drugs, decitabine and cedazuridine. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone ma…

From ClinicalTrials.gov, last updated 2026-11-04. Full record, eligibility and contacts (opens in a new tab)

Industry funding

E.r. Squibb & Sons, L.l.c. reported $3.2M in research payments for this study in 2025 (108 payments).

Products named: Idhifa

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.